SpringWorks rises as FDA grants priority review to genetic disorder drug

SpringWorks Therapeutics

28/08/2024 14:58

** Shares of SpringWorks Therapeutics  SWTX.O  rise 2.5% to
$42.1
    ** Co says the U.S. Food and Drug Administration has granted
Priority Review to its application seeking approval for its
experimental drug to treat NF1-PN in adult and pediatric
patients 
    ** NF1-PN is a rare genetic disorder characterized by
changes in skin coloring and the growth of tumors along nerves
in the skin, brain and other parts of the body
    ** FDA is set to make a decision on the drug,  mirdametinib,
by February 28, 2025 - SWTX
    ** FDA is not currently planning to hold an advisory
committee meeting to discuss the application - SWTX
    ** Including session moves, stock had risen 13.3% YTD

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))